Introduction
Prostate cancer (PCa) is the most common malignancy in western males. 1 It is estimated that 164,690 new PCa cases and 29,430 PCa-related deaths will occur in 2018 in USA. 1 So far, prostate-specific antigen (PSA) has been mostly used for early detection and recurrence evaluation as a biomarker. Gleason score is a classical prognostic factor but not sufficient to portray the complexity of clinical prognosis. 2 The heterogeneous genomic property of PCa can lead to the difficulty in survival prognosis and therapy monitoring. Therefore, there is an urgent need for novel effective parameters to predict outcomes for treatment decision. Recently, a number of biomarkers about PCa have been investigated and established in patient cohort studies. [3] [4] [5] [6] In comparison with cancer tissues, serum is an ideal source of biomarkers because of the convenience in routine clinical measurement. 7 Scientists have been trying for decades to seek the biomarkers among the different kinds of molecules such as proteins, noncoding RNAs, and chemical compounds. 8 Interestingly, we notice that alkaline phosphatase (ALP), a classical parameter, also has a great potential in the prognosis of PCa.
Methods search strategy
This meta-analysis adhered to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 13 A comprehensive literature search in the PubMed, Embase, and Web of Science was conducted from the databases onset to February 5, 2018 . The key words were as follows: ("prostate neoplasms [MeSH] " OR "prostate cancer") AND "alkaline phosphatase" or "ALP" AND ("prognosis [MeSH] " OR "survival" OR "outcome"). The language of studies was not restricted. Additional relevant publications were also manually searched based on the reference lists.
study selection inclusion and exclusion criteria
Studies were included only if they met the following criteria: 1) clinical cohort/trial evaluated the prognostic ability of ALP in PCa; 2) studies compared ALP with other prognostic models and reported survival outcomes such as overall survival (OS), progression-free survival (PFS), and cancer-specific survival (CSS); 3) reported original HR with 95% CI or the HR could be calculated from sufficient data; 4) articles with the most complete information if there were several studies among overlapping cohorts or time periods.
The exclusion criteria were 1) duplicate publications; 2) studies based on less than 20 patients; 3) laboratory studies, animal studies, letters, or review articles.
assessment of study quality Two investigators (DL and XH) independently reviewed all the relevant articles, then evaluated the methodological quality of observational studies using Newcastle-Ottawa Quality Assessment Scale (NOS) assessment tool, including selection, comparability, and outcomes.
14 The Jadad composite scale was utilized to assess randomized controlled trials (RCTs). 15 The NOS score ≥7 or Jadad score ≥4 indicated high quality. Disagreements in data collection and quality assessment were resolved through consensus by involving a third author (HL).
Data extraction
The baseline and outcome data were obtained from each study: first author's surname, year of publication, study design, country, sample size, age, PSA level, cutoff value, follow-up time, outcomes, and HRs with 95% CI. If the HRs of both univariate and multivariate analysis were available, only the latter was used.
statistical analysis
HRs with 95% CI from all eligible studies were pooled via a meta-analysis to access the strength of ALP to survival endpoints. The Cochran Q test was used to determine the heterogeneity among studies. A P value <0.10 indicated heterogeneity. The inconsistency (I 2 ) was also calculated to evaluate heterogeneity. An I 2 value >50% indicated the presence of statistical heterogeneity. The random-effect model (DerSimonian and Laird method) was used to calculate pooled results when there was heterogeneity among included studies; otherwise, the fixed-effect model was used. To seek deeper relationship between ALP and OS, we conducted subgroup analyses on study type, cutoff value, sample size, and region of study. Furthermore, to test the reliability of the results, sensitivity analysis was conducted by removing each single study in turn. Begg's test with funnel plots was used to measure publication bias. The P value >0.05 indicated no potential publication bias. The Stata 12.0 software (StataCorp, College Station, TX, USA) was used to perform all the statistical analyses. A two-sided P value <0.05 was considered as statistically significant.
Results

studies selection and evaluation
The flowchart of articles searching process is shown in Figure 1 . A total of 1,107 relevant citations were initially retrieved by the search strategy as described above in Table S1 revealing the NOS score were equal or greater than 6 in all 48 observational studies and the Jadad score was over 4 in all six RCTs.
Overall analysis
Meta-analysis on Os Figure 2B ), which demonstrates a significant relationship among five RCTs. There were three studies comparing the decrease in serum ALP level and OS, whose pooled HR was 0.56 (95% CI: 0.42-0.75, Figure 3A) . Besides, five studies investigated the relationship between bone-specific ALP (BAP) and OS in patients with PCa. The pooled HR for BAP and OS is 1.65 (95% CI: 1.41-1.92, Figure 3B ).
Meta-analysis on Css
Seven studies provided sufficient data on ALP and CSS outcome. The pooled HR was 1.002 (95% CI: 0.998-1.005) via a random effects model, and the potential heterogeneity among studies was observed (I 2 =75.4%, P<0.001, Figure 4A ).
Meta-analysis on PFs
Nine studies reported the data concerning the association between ALP and PFS. Meta-analysis adopting the random effects model revealed that elevated ALP was significantly associated with shorter PFS (HR=1.60, 95% CI: 1.13-2.26) with potential heterogeneity (I 2 =82.1%, P<0.001, Figure 4B ).
subgroup analyses
Moreover, we conducted a subgroup meta-analysis on different study designs. Although the main results were not affected by different study design, heterogeneity still existed in both prospective cohorts (HR=1.76, 95% CI: 1.42-2.19, Figure S1A ) and retrospective studies (HR=1.58, 95% CI: 1.24-2.00, Figure S1B ). In epidemiological studies, ethnicity difference was usually recognized as a critical source of bias. Notably, we also found the elevated serum ALP was significantly associated with poor OS among the studies in Asia ( Figure S1C ), Europe ( Figure S1D ), and North America ( Figure S1E ). Furthermore, we performed subgroup analysis in different cutoff values ( Figure S1F , G) and sample sizes ( Figure S1H, I ). To sum up, the pooled HRs indicated that higher ALP was significantly associated with poorer OS in all subgroups of patients with PCa (Table 2) .
sensitivity analysis
The sensitivity analysis was performed by the sequential deletion of any individual article to measure the effects of each individual study. The results showed that the overall HRs were not significantly influenced by individual study, as shown in Figure 5 , indicating the robustness of the results in our meta-analysis.
assessment of publication bias
Begg's test was performed to evaluate the publication bias of the inclusion studies ( Figure 6 ). The P-values of Begg's test for OS (observational studies and RCTs) were 0.747 and 0.086, respectively, indicating that there was no significant publication bias.
Discussion
Serum ALP level is a simple and rapid laboratory test in routine clinical practice. An ideal prognostic biomarker can be used to determine prognosis, monitor response to therapy, and postoperative surveillance. 70 The high ALP level has been reported related to the poor survival in colorectal cancer. 71 The elevation of ALP is also an independent risk factor in the bone metastasis of gastric cancer and bladder cancer. 72, 73 However, the underlying mechanisms of ALP in patients with PCa remain unclear. A possible explanation is that when the PCa starts metastasis, ALP reflects bone turnover, osteoblast activity, and the osteoid formation in adjacent bone tissues.
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Thus, ALP may be an indicator of bone metastatic tumor load.
In this meta-analysis, based on the existing data from 63 included studies, the pooled results indicated that high baseline ALP was associated with obviously poor OS and PFS (HR=1.60, 95% CI: 1.13-2.26) in patients with PCa. As presented in Table 1 , most included studies used multivariate cox model to explore ALP and survival. After being adjusted for other factors such as tumor stage/grade, PSA, Gleason score, hemoglobin, and metastasis, the original results of ALP were objective and reliable. The meta-analysis on both observational studies (HR=1.74, 95% CI: 1.47-2.06) and RCTs (HR=1.15, 95% CI: 1.02-1.30) reached the consistent conclusions about ALP and OS. In addition, high serum BAP was also significantly related to poor OS (HR=1.76, 95% CI: 1.42-2.15). However, our result revealed that there was no association between ALP and CSS in patients with PCa (HR=1.002, 95% CI: 0.998-1.005). We hypothesize that ALP is more sensitive in reflecting bone metastasis, so, high serum ALP is significantly associated with PFS of PCa. PCa patients with bone metastasis and other underlying diseases may lead to poorer OS. Whereas the seven studies about CSS Halabi et al 2013 16 Goldkorn et al 2014 17 Schellhammer et al 2013 18 Humphrey et al 2006 19 Halabi et al 2014 22 Klaff et al 2016 23 Klaff et al 2016 23 Miyamoto et al 2012 24 Kita et al 2013 25 Bilen et al 2017 26 Omlin et al 2013 27 Nakashima et al 2000 28 Templeton et al 2014 29 van Soest et al 2015 30 Sonpavde et al 2014 31 Halabi et al 2003 32 Shiota et al 2014 33 Oh et al 2017 34 Chi et al 2016 36 Nozawa et al 2015 37 Pienta et al 1997 38 Reynard et al 1995 39 Thatai et al 2004 40 Etchebehere et al 2016 42 George et al 2001 43 Buttigliero et al 2017 44 Shigeta et al 2016 45 Wyatt et al 2004 46 Sonpavde et al 2012 48 Halabi et al 2004 49 Oh et al 2011 50 Hammerich et al 2017 Fizazi et al 2015 67 Rahbar et al 2018 68 Sartor et al 2017 69 Brasso et al 2006 35 Nozawa et al 2015 37 Ramankulov et al 2007 47 Cook et al 2006 53 Izumi et al 2012 Park et al 2012 54 Yamada et al 2010 55 Kamiya et al 2010 56 Mohammed et al 2015 57 Akimoto et al 1997 58 Koo et al 2015 59 Kato et al 2016 60 Nozawa et al 2015 37 Thatai et al 2004 40 Etchebehere et al 2016 42 Buttigliero et al 2017 44 Shigeta et al 2016 45 Bando et al 2017 62 Pelger et al 1996 63 Han and Hong 2014 64 Goodman et al 2011 Qu et al 2013 21 Mikah et al 2016 22 Klaff et al 2016 23 Klaff et al 2016 23 Miyamoto et al 2012 24 Kita et al 2013 25 Bilen et al 2017 26 Omlin et al 2013 27 Nakashima et al 2000 28 Van soest et al 2015 30 Templeton et al 2014 29 Sonpavde et al 2014 31 Halabi et al 2003 32 Shiota et al 2014 33 Oh et al 2017 34 Chi et al 2016 36 Pienta et al 1997 38 Nozawa et al 2015 37 Reynard et al 1995 39 Thatai et al 2004 40 Etchebehere et al 2016 42 George et al 2001 43 Buttigliero et al 2017 44 Shigeta et al 2016 45 Wyatt et al 2004 46 Sonpavde et al 2012 48 Halabi et al 2004 49 Oh et al 2011 50 Hammerich et al 2017 52 D'Amico et al 2005 61 Matsuyama et al 2014 66 Kato et al 2016 60 Vesalainen et al 1995 41 Halabi et al 2013 16 Meta-analysis estimates, given named study is omitted Figure 4A ) were all retrospective in the study design. The sample size was also relatively smaller for CSS than OS. Thus, we should carefully interpret the result of ALP and CSS. The results of subgroup analyses on different study types, regions, cutoff values, and sample sizes were all in accordance with the main findings. The sensitivity analysis and publication bias tests' outcomes also supported our results. Therefore, we may recommend ALP as a valuable prognostic marker for PCa treatment decision and adjustment. Compared with the positron emission tomography-computed tomography, ALP combined with bone scintigraphy may also be useful to assess the metastatic burden and survival possibility of PCa with a remarkably less expensive cost. To our knowledge, this is the first meta-analysis on ALP and the prognosis of PCa. However, there are still a couple of limitations to be stated. First, although the language was not restricted during the searching process, all the included studies were in English, which might lead to language bias. Second, although sensitivity analysis supported the stability of our results, the findings should be cautiously interpreted. Heterogeneity among studies was found in overall and subgroup analyses. It was probably owing to multivariate factors in some included studies. Third, the data of ALP on other prognostic clinical parameters such as metastasis and all-cause mortality are lacking at present. Meanwhile, the retrospective design in 23 included studies (Table 1) may cause potential recall bias. Thus, more large-scale prospective studies are warranted to testify the prognostic ability of ALP in PCa in the future. Moreover, BAP will also be a potential prognostic marker in PCa, which needs verification as well. 
Conclusion
In spite of the limitations mentioned above, the results of this study present the conclusion that high serum ALP is significantly associated with poor OS and PFS of PCa, but there is no obvious relation between ALP and CSS. ALP level is an efficient and convenient biomarker for PCa prognosis.
